Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA OK's Horizon Pharma's arthritis drug Duexis

This article was originally published in Scrip

Executive Summary

Horizon Pharma gained US approval of Duexis, a fixed-dose combination of ibuprofen 800mg and famotidine 26.6mg indicated for the relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. It also is approved as a therapy to decrease the risk of developing upper gastrointestinal ulcers.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts